vs
AIM ImmunoTech Inc.（AIM）与Aligos Therapeutics, Inc.（ALGS）财务数据对比。点击上方公司名可切换其他公司
Aligos Therapeutics, Inc.的季度营收约是AIM ImmunoTech Inc.的8.0倍（$169.0K vs $21.0K）。Aligos Therapeutics, Inc.净利率更高（-11763.9% vs -19881.0%，领先8117.0%）。AIM ImmunoTech Inc.同比增速更快（-53.3% vs -72.1%）。过去两年AIM ImmunoTech Inc.的营收复合增速更高（-27.5% vs -50.7%）
AIM ImmunoTech是一家总部位于美国佛罗里达州奥卡拉的生物制药企业，前身是Hemispherx Biopharma，1990年成立，目前专注于研发用于治疗多种癌症、各类病毒感染以及免疫缺陷疾病的创新疗法。
Aligos Therapeutics是一家临床阶段生物制药企业，专注于开发针对流行性肝病与病毒感染的新型靶向疗法，核心管线覆盖慢性乙型肝炎、非酒精性脂肪性肝炎等适应症，通过自主研发推进药物落地，满足全球未被满足的医疗需求。
AIM vs ALGS — 直观对比
营收规模更大
ALGS
是对方的8.0倍
$21.0K
营收增速更快
AIM
高出18.8%
-72.1%
净利率更高
ALGS
高出8117.0%
-19881.0%
两年增速更快
AIM
近两年复合增速
-50.7%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $21.0K | $169.0K |
| 净利润 | $-4.2M | $-19.9M |
| 毛利率 | — | — |
| 营业利润率 | -14057.1% | -12907.7% |
| 净利率 | -19881.0% | -11763.9% |
| 营收同比 | -53.3% | -72.1% |
| 净利润同比 | 30.0% | 75.8% |
| 每股收益（稀释后） | $-6.46 | $4.23 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AIMALGS
| Q4 25 | $21.0K | $169.0K | ||
| Q3 25 | $26.0K | $741.0K | ||
| Q2 25 | $25.0K | $965.0K | ||
| Q1 25 | $16.0K | $311.0K | ||
| Q4 24 | $45.0K | $606.0K | ||
| Q3 24 | $35.0K | $1.3M | ||
| Q2 24 | $50.0K | $1.1M | ||
| Q1 24 | $40.0K | $694.0K |
净利润AIMALGS
| Q4 25 | $-4.2M | $-19.9M | ||
| Q3 25 | $-3.3M | $-31.5M | ||
| Q2 25 | $-2.8M | $-15.9M | ||
| Q1 25 | $-3.7M | $43.1M | ||
| Q4 24 | $-6.0M | $-82.2M | ||
| Q3 24 | $-3.7M | $-19.3M | ||
| Q2 24 | $-1.8M | $5.1M | ||
| Q1 24 | $-5.8M | $-34.9M |
营业利润率AIMALGS
| Q4 25 | -14057.1% | -12907.7% | ||
| Q3 25 | -9411.5% | -3827.4% | ||
| Q2 25 | -10584.0% | -1924.0% | ||
| Q1 25 | -22618.8% | -6187.5% | ||
| Q4 24 | -13011.1% | -3393.2% | ||
| Q3 24 | -12825.7% | -1610.5% | ||
| Q2 24 | -7388.0% | -2489.5% | ||
| Q1 24 | -14335.0% | -3176.7% |
净利率AIMALGS
| Q4 25 | -19881.0% | -11763.9% | ||
| Q3 25 | -12630.8% | -4256.0% | ||
| Q2 25 | -11176.0% | -1643.8% | ||
| Q1 25 | -23156.3% | 13854.7% | ||
| Q4 24 | -13260.0% | -13556.1% | ||
| Q3 24 | -10571.4% | -1540.7% | ||
| Q2 24 | -3672.0% | 477.0% | ||
| Q1 24 | -14542.5% | -5023.5% |
每股收益（稀释后）AIMALGS
| Q4 25 | $-6.46 | $4.23 | ||
| Q3 25 | $1.57 | $-3.04 | ||
| Q2 25 | $-3.68 | $-1.53 | ||
| Q1 25 | $-0.05 | $-2.11 | ||
| Q4 24 | $-21.80 | $-13.10 | ||
| Q3 24 | $-6.00 | $-3.07 | ||
| Q2 24 | $-3.00 | $0.81 | ||
| Q1 24 | $-0.12 | $-5.58 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.0M | $77.8M |
| 总债务越低越好 | $4.5M | — |
| 股东权益账面价值 | $-9.8M | $53.5M |
| 总资产 | $5.8M | $88.5M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AIMALGS
| Q4 25 | $3.0M | $77.8M | ||
| Q3 25 | $2.4M | $99.1M | ||
| Q2 25 | $835.0K | $122.9M | ||
| Q1 25 | $2.2M | $137.9M | ||
| Q4 24 | $4.0M | $56.9M | ||
| Q3 24 | $7.2M | $74.9M | ||
| Q2 24 | $10.1M | $94.5M | ||
| Q1 24 | $10.9M | $112.7M |
总债务AIMALGS
| Q4 25 | $4.5M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $2.7M | — | ||
| Q1 25 | $2.4M | — | ||
| Q4 24 | $2.8M | — | ||
| Q3 24 | $3.3M | — | ||
| Q2 24 | $3.3M | — | ||
| Q1 24 | $3.3M | — |
股东权益AIMALGS
| Q4 25 | $-9.8M | $53.5M | ||
| Q3 25 | $-6.1M | $71.8M | ||
| Q2 25 | $-6.5M | $101.9M | ||
| Q1 25 | $-3.9M | $116.4M | ||
| Q4 24 | $-1.3M | $-29.0M | ||
| Q3 24 | $2.9M | $50.1M | ||
| Q2 24 | $6.1M | $67.2M | ||
| Q1 24 | $4.8M | $59.8M |
总资产AIMALGS
| Q4 25 | $5.8M | $88.5M | ||
| Q3 25 | $5.5M | $109.8M | ||
| Q2 25 | $4.1M | $134.7M | ||
| Q1 25 | $6.2M | $150.7M | ||
| Q4 24 | $8.6M | $70.1M | ||
| Q3 24 | $13.6M | $88.4M | ||
| Q2 24 | $15.7M | $108.8M | ||
| Q1 24 | $16.2M | $127.9M |
负债/权益比AIMALGS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.13× | — | ||
| Q2 24 | 0.54× | — | ||
| Q1 24 | 0.69× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.0M | $-21.7M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流AIMALGS
| Q4 25 | $-2.0M | $-21.7M | ||
| Q3 25 | $-5.1M | $-24.3M | ||
| Q2 25 | $-1.5M | $-15.5M | ||
| Q1 25 | $-2.4M | $-20.9M | ||
| Q4 24 | $-4.0M | $-18.4M | ||
| Q3 24 | $-3.1M | $-20.1M | ||
| Q2 24 | $-3.0M | $-19.5M | ||
| Q1 24 | $-4.8M | $-22.7M |
现金转化率AIMALGS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -0.49× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -3.85× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
